In Brief: NeoPath
This article was originally published in The Gray Sheet
Executive Summary
NeoPath: Corning Clinical Laboratories will use the company's AutoPap 300 QC automated cervical cytology reader to conduct quality control for Pap smear screening. Corning, which operates 25 labs serving 44 states in the U.S., expects to install the first AutoPap system in its Wood Dale, Illinois facility in January. The agreement is the second for NeoPath since obtaining FDA approval for AutoPap on Sept. 29 ("The Gray Sheet" Oct. 9, p. 6). Earlier in October, the company signed a deal under which SmithKline Beecham Clinical Laboratories will install the automated system in its labs beginning in January...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.